Source: Journal of Clinical Oncology. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, TRATAMENTO (RESULTADOS), METÁSTASE NEOPLÁSICA, ANTINEOPLÁSICOS (CLASSIFICAÇÃO)
ABNT
MACKEY, John R. et al. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, v. 33, n. 2, p. 141-148, 2015Tradução . . Disponível em: https://doi.org/10.1200/JCO.2014.57.1513. Acesso em: 10 nov. 2024.APA
Mackey, J. R., Ramos-Vazquez, M., Oleg Lipatov,, McCarthy, N., Krasnozhon, D., Semiglazov, V., et al. (2015). Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, 33( 2), 141-148. doi:10.1200/JCO.2014.57.1513NLM
Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513Vancouver
Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513